Isis' partnership strategy has enabled the Company to build a broad product pipeline and
to create an annuity of milestone payments and royalty revenues while limiting development
expenses. This strategy enables the Company to remain focused on research and development
and to discover new drugs and expand Isis' and Isis' partners pipelines. Please check here
for updates on news, event participation and important scientific publications from our partners.
| 2010-08-03 |
Excaliard Announces Positive Data From Phase 2 Clinical Trial of its Anti-Scarring Drug, EXC 001 |
| 2010-07-26 |
iCo Therapeutics Inc. receives Health Canada Clearance to Conduct Phase II DME Trial with iCo-007 |
| 2010-07-15 |
New Therapeutic Avenues for Spinal Muscular Atrophy in Development by Isis Pharmaceuticals, Inc. - First SMA Mouse Model Studies Published on Drug Candidate |
| 2010-07-12 |
CSHL Researchers Demonstrate Efficacy of Antisense Therapy for Spinal Muscular Atrophy |
| 2010-06-21 |
OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 in Men with Metastatic Prostate Cancer |
| 2010-06-07 |
OncoGenex Pharmaceuticals Announces Final Results from Phase 1 Trial Evaluating OGX-427 as a Treatment for Solid Tumors |
| 2010-05-27 |
Regulus Therapeutics Receives Exclusive License for Intellectual Property to microRNA-21 for Diseases of the Heart, Liver, and Kidney |
| 2010-05-25 |
iCo Therapeutics Inc. Enters Into Technology Transfer Agreement With Isis Pharmaceuticals, Inc. for iCo-007 |
| 2010-05-19 |
Atlantic Healthcare Announces it is Commencing Manufacture and International Supply of Alicaforsen for Inflammatory Bowel Disease Under Named Patient Supply Regulations |
| 2010-05-17 |
iCo Therapeutics iCo-007 Phase I Clinical Trial Meets Primary Endpoint |
| 2010-05-04 |
ATL Business Operations Update |
| 2010-04-15 |
Regulus Therapeutics Presents New Pre-clinical Data on microRNA Therapeutics for Diabetes |
| 2010-03-29 |
Regulus Therapeutics and Collaborators Publish Pre-clinical in Vivo Efficacy Data on microRNA Therapeutics Targeting microRNA-10b in Models of Breast Cancer Metastasis |
| 2010-03-25 |
Data from OncoGenex Pharmaceuticals' Product Candidate OGX-427 to be Presented at the American Society of Clinical Oncology Annual Meeting |
| 2010-03-24 |
ATL1102 License Agreement with Teva Pharmaceutical Industries Ltd. |
| 2010-03-17 |
Regulus Announces U.S. Allowance of Stanford Patent Application Covering miR-181a Function in Immune Cells |
| 2010-03-15 |
Peer-reviewed Research Elucidates Function of Hsp27; Supports OGX-427 Approach Targeting Cancer Treatment Resistance |
| 2010-03-01 |
Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer |
| 2010-02-25 |
Regulus Therapeutics and GlaxoSmithKline Establish New Collaboration to Develop and Commercialize microRNA Therapeutics Targeting miR-122 |
| 2010-02-25 |
The European Medicines Agency is in Overall Agreement with OncoGenex Pharmaceuticals' Development Plan for OGX-011 in Patients with Metastatic Castrate-Resistant Prostate Cancer |
| 2010-01-15 |
Regulus Therapeutics Present New Pre-clinical Data from Multiple Therapeutic Programs at Keystone Symposium |
| 2010-01-06 |
OncoGenex Announces that a Randomized, Investigator-Sponsored Phase 2 Study Evaluating OGX-427 Has Received Grant Funding |
| 2010-01-05 |
Excaliard Initiates Phase 2 Trials in U.S. for its Skin Scarring Drug EXC 001 |
| 2009-12-21 |
Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications |
| 2009-12-17 |
Regulus Therapeutics Receives Exclusive License for Intellectual Property on Immuno-inflammatory microRNAs from the California Institute of Technology |
| 2009-12-11 |
iCo Therapeutics Provides Phase 1 Diabetic Macular Edema (DME) Clinical Trial Update and Phase 2 Trial Guidance |
| 2009-12-09 |
Regulus Therapeutics Inc. Presents: "MicroRNA: The Year in Review and a Look Ahead |
| 2009-11-19 |
Altair Therapeutics Announces Commencement of a Multi-Center Phase IIa Clinical Trial of Inhaled AIR645 to Treat Asthma |
| 2009-11-11 |
Altair Therapeutics Secures $17 Million Financing |
| 2009-10-28 |
Regulus Announces U.S. Allowance of Fundamental microRNA Therapeutics Patent Application |
| 2009-10-12 |
Update: ATL1103 on Track to Move Into Clinical Development |
| 2009-10-06 |
FDA Grants Additional Fast Track Designation for OGX-011 in Combination with First Line Chemotherapy |
| 2009-09-14 |
Achaogen Announces ACHN-490 Clinical Data at the 49th Annual ICAAC Meeting |
| 2009-09-14 |
Altair Therapeutics Reports Successful Phase I Study of Inhaled AIR645 |
| 2009-08-20 |
Verva Announces License of Key FGFR Intellectual Property to Isis Pharmaceuticals, Inc. for the Treatment of Obesity and Other Diseases |
| 2009-08-13 |
OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer |
| 2009-08-11 |
Alnylam and Regulus Receive Notice of Allowance from United States Patent and Trademark Office for New Patent Covering microRNA Therapeutics |
| 2009-08-10 |
OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011 |
| 2009-07-07 |
iCo Therapeutics Diabetic Macular Edema Clinical Trial Update |
| 2009-07-02 |
iCo Therapeutics Publishes Review of Diabetic Retinopathy Treatment |
| 2009-06-24 |
OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer |
| 2009-06-18 |
Antisense Therapeutics Drug ATL1101 Enhances Effect of Existing Chemotherapy Treatment on Prostate Tumours |
| 2009-05-30 |
OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer |
| 2009-05-30 |
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial |
| 2009-05-18 |
Altair Therapeutics Reports Successful Completion of Phase I Study of Inhaled AIR645 |
| 2009-05-14 |
OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427 |
| 2009-05-14 |
Altair Therapeutics Appoints Dr. Joel Martin President and CEO |
| 2009-05-11 |
OncoGenex Pharmaceuticals' Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting |
| 2009-04-28 |
OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer |
| 2009-04-14 |
Novosom Publishes Data on Novel Anti-inflammatory Therapeutic Approach Targeting CD40 |
| 2009-03-17 |
iCo Therapeutics iCo-007 Second Cohort Results to be Presented at Cleveland Clinic Ocular Conference |
| 2009-02-19 |
iCo Therapeutics iCo-007 Results to be Presented at Prestigious Ocular Conference |
| 2009-02-12 |
Antisense Therapeutics Projects Update |
| 2009-02-09 |
iCo Therapeutics Closes $1.3 Million Private Placement |
| 2009-02-04 |
OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer |
| 2009-02-03 |
Achaogen Initiates Phase 1 Trial of ACHN-490 for Treatment of Multi-Drug Resistant Gram-Negative Bacterial Infections |
| 2008-12-03 |
OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study |
| 2008-10-15 |
ATL1101 Suppresses Tumour Growth in Key Mouse Models of Prostate Cancer |
| 2008-10-13 |
OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011 |
| 2008-09-22 |
iCo Therapeutics Provides Interim Trial Results (Diffuse Diabetic Macular Edema) |
| 2008-09-15 |
Teva to Present New Treatment Data at World Congress for Multiple Sclerosis |
| 2008-08-28 |
ATL/TV1102 Phase IIa Multiple Sclerosis Trial Findings to Be Presented at Leading World Congress on MS |
| 2008-08-26 |
Novosom AG Acquires Exclusive License from Isis Pharmaceuticals, Inc. for CD40-targeted Antisense Inhibitors |
| 2008-08-22 |
FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 |
| 2008-07-14 |
OncoGenex Receives Completed Special Protocol Assessment for Primary Registration Study of Lead Drug Candidate OGX-011 |
| 2008-07-08 |
Atlantic Healthcare Receives Orphan Drug Designation for Alicaforsen for the Treatment of Pouchitis |
| 2008-07-03 |
OncoGenex Increases Economic Interest in Lead Cancer Drug OGX-011 |
| 2008-06-30 |
Teva & ANP Announce that ATL/TV1102, a Novel Drug for the Treatment of Relapsing Remitting Multiple Sclerosis (RRMS), Demonstrated Significant Reduction in Disease Activity |
| 2008-06-02 |
OncoGenex reports that low serum clusterin levels were predictive of survival in preliminary analyses of Phase 2 study of lead drug candidate OGX-011 |
| 2008-05-16 |
OncoGenex Reports Updated Survival Data on OGX-011 in a Second-Line Chemotherapy Trial for Patients with Prostate Cancer |
| 2008-05-06 |
Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University |
| 2008-04-17 |
ANP completes ATL1102 Phase IIa Multiple Sclerosis Trial |
| 2008-02-11 |
Antisense Therapeutics Ltd Licenses ATL1102 to Teva Pharmaceutical Industries Ltd |
